Saturday 17 October 2026
Export HALO’s income statement to Excel — free account
Halozyme Therapeutics, Inc.
HALO Healthcare Biotechnology
Halozyme Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 37.6% from fiscal 2024. In the quarter to June 2026, revenue grew 47.7%, EPS grew 44.1%, free cash flow grew 141.2% and total debt rose 42.2%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.
121.84
0.33
+0.27%
Follow HALO
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
124.50% | 153.59% | 99.40% | 173.67% | |
Piotroski F-Score |
8 | 5 | 5 | 5 | |
| 27.45% | 13.81% | 14.33% | 17.86% | ||
ROIC |
35.11% | 14.31% | 15.64% | 18.13% | |
Return on Tangible Assets |
105.78% | 43.39% | 48.31% | 61.47% | |
Average Days of Receivables |
101.62 | 115.33 | 110.82 | 100.00 | |
Free Cash Flow per Share |
6.31 | 5.38 | 5.65 | 6.87 | |
Free Cash Flow |
739.68 | 644.59 | 667.65 | 806.22 | |
Capital Expenditures |
128.68 | (6.97) | (9.76) | (12.37) | |
| Other line items | |||||
Cash ROIC |
27.23% | 27.61% | 24.89% | 31.98% | |
Accounts Receivable Turnover |
3.93 | 3.73 | 3.96 | 4.31 | |
Accounts Payable Turnover |
13.84 | 14.69 | 15.19 | 13.83 | |
Inventory Turnover |
1.21 | 1.44 | 1.62 | 1.84 | |
Average Days of Payables |
29.19 | 33.34 | 19.82 | 29.47 | |
Days of Inventory on Hand |
353.10 | 281.56 | 218.58 | 171.17 | |
Tax Rate |
(0.20) | (0.32) | (0.31) | (0.29) | |
Research and Development Expense of Revenue |
5.63% | 26.23% | 25.00% | 23.28% | |
Selling, General and Administrative Expense of Revenue |
13.86% | 14.83% | 14.76% | 14.30% | |
Share Based Compensation of Revenue |
3.74% | 3.69% | 3.81% | 3.79% | |
Interest Coverage |
41.53 | 25.87 | 26.79 | 29.41 | |
Operating CF/Net income |
1.03 | 2.06 | 1.94 | 1.98 | |
Depreciation/Fixed assets |
1.17 | 1.12 | 1.31 | 1.45 | |
Capex/Depreciation |
1.54 | (0.08) | (0.09) | (0.10) | |
Revenue per Share |
10.60 | 11.65 | 12.77 | 14.19 | |
Operating CF per Share |
5.21 | 5.44 | 5.73 | 6.98 | |
Capex per Share |
1.10 | (0.06) | (0.08) | (0.11) | |
Capex to Sales |
(0.10) | 0.01 | 0.01 | 0.01 |
Columns are period end dates